Sulbactam

Sulbactam
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a693021
Routes of; administration	Intravenous, intramuscular
ATC code	J01CG01 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only);
Pharmacokinetic data
Protein binding	29%
Elimination half-life	0.65–1.20 hrs
Excretion	Mainly kidneys (41–66% within 8 hrs)
Identifiers
	IUPAC name (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide;
CAS Number	68373-14-8 ;
PubChem CID	130313;
ChemSpider	115306 ;
UNII	S4TF6I2330;
KEGG	D08533 ;
ChEBI	CHEBI:9321 ;
ChEMBL	ChEMBL403 ;
CompTox Dashboard (EPA)	DTXSID1023605 ;
ECHA InfoCard	100.063.506
Chemical and physical data
Formula	C8H11NO5S
Molar mass	233.24 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	148 to 151 °C (298 to 304 °F)
	SMILES O=S2(=O)C([C@@H](N1C(=O)C[C@H]12)C(=O)O)(C)C;
	InChI InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1 ; Key:FKENQMMABCRJMK-RITPCOANSA-N ;
	(verify)

Sulbactam is a β-lactamase inhibitor. This drug is given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics.^[1]

It was patented in 1977 and approved for medical use in 1986.^[2]

^ Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR (August 2007). "Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase". Biochemistry. 46 (31): 8980–8987. doi:10.1021/bi7006146. PMC 2596720. PMID 17630699.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 492. ISBN 9783527607495.